WallStreetZenWallStreetZen

NYSE: NVST
Envista Holdings Corp Stock

$21.38-0.17 (-0.79%)
Updated Mar 28, 2024
NVST Price
$21.38
Fair Value Price
N/A
Market Cap
$3.67B
52 Week Low
$20.00
52 Week High
$40.92
P/E
-35.63x
P/B
0.88x
P/S
1.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.57B
Earnings
-$100.20M
Gross Margin
56.1%
Operating Margin
0.33%
Profit Margin
-3.9%
Debt to Equity
0.58
Operating Cash Flow
$276M
Beta
1.03
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NVST Overview

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures and markets dental products in the United States and internationally. The company operates in two segment, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare systems, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Pelton & Crane, Kerr, MetrexTM, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.

Zen Score

–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NVST is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVST is good value based on its book value relative to its share price (0.88x), compared to the US Medical Instruments & Supplies industry average (3.75x)
P/B vs Industry Valuation
NVST is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NVST due diligence checks available for Premium users.

Be the first to know about important NVST news, forecast changes, insider trades & much more!

NVST News

Valuation

NVST price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-35.63x
Industry
53.11x
Market
44.51x

NVST price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.88x
Industry
3.75x
NVST is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NVST's financial health

Profit margin

Revenue
$645.6M
Net Income
-$217.4M
Profit Margin
-33.7%
NVST's Earnings (EBIT) of $8.50M... subscribe to Premium to read more.
Interest Coverage Financials
NVST's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$6.6B
Liabilities
$2.4B
Debt to equity
0.58
NVST's short-term assets ($1.74B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVST's short-term assets ($1.74B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVST's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$102.0M
Investing
-$12.6M
Financing
$3.3M
NVST's operating cash flow ($275.70M)... subscribe to Premium to read more.
Debt Coverage Financials

NVST vs Medical Stocks

TickerMarket Cap1d %P/EP/B
NVST$3.67B-0.79%-35.63x0.88x
AZTA$3.36B+1.43%-182.67x1.38x
HAE$4.33B+1.50%34.14x4.60x
MMSI$4.39B+0.38%46.19x3.65x
ICUI$2.59B+4.31%-87.25x1.22x

Envista Holdings Stock FAQ

What is Envista Holdings's quote symbol?

(NYSE: NVST) Envista Holdings trades on the NYSE under the ticker symbol NVST. Envista Holdings stock quotes can also be displayed as NYSE: NVST.

If you're new to stock investing, here's how to buy Envista Holdings stock.

What is the 52 week high and low for Envista Holdings (NYSE: NVST)?

(NYSE: NVST) Envista Holdings's 52-week high was $40.92, and its 52-week low was $20.00. It is currently -47.75% from its 52-week high and 6.9% from its 52-week low.

How much is Envista Holdings stock worth today?

(NYSE: NVST) Envista Holdings currently has 171,550,131 outstanding shares. With Envista Holdings stock trading at $21.38 per share, the total value of Envista Holdings stock (market capitalization) is $3.67B.

Envista Holdings stock was originally listed at a price of $27.95 in Sep 18, 2019. If you had invested in Envista Holdings stock at $27.95, your return over the last 4 years would have been -23.51%, for an annualized return of -6.48% (not including any dividends or dividend reinvestments).

How much is Envista Holdings's stock price per share?

(NYSE: NVST) Envista Holdings stock price per share is $21.38 today (as of Mar 28, 2024).

What is Envista Holdings's Market Cap?

(NYSE: NVST) Envista Holdings's market cap is $3.67B, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Envista Holdings's market cap is calculated by multiplying NVST's current stock price of $21.38 by NVST's total outstanding shares of 171,550,131.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.